PLEKHB1

Across TCGA pan-cancer cohorts, PLEKHB1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PLEKHB1 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PLEKHB1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLEKHB1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC and UCEC are the cancer types where PLEKHB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.131	0.707	<.001	30	view →
UCEC	DFS	Median	All	1.000	0.830	.022	14	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PLEKHB1–LIHC (OS)

Open the LIHC breakdown →